The gene editing technology developer is the latest spinout emerging out of the lab of David Liu at Broad Institute.

Prime Medicine, a US-based gene-editing technology developer spun out of Broad Institute, has emerged from stealth with $315m of series A and B funding. The company raised $115m in a series A round backed by GV, a corporate venturing subsidiary of internet and technology group Alphabet, together with Arch Venture Partners, Newpath Partners and Fidelity’s…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.